Abstract: MDFT is a family-based intervention for adolescent substance abuse and associated mental health and behavioural problems (Liddle, 2010). Integrative in several ways, MDFT uses an ecological or contextual conceptual framework to understand the developmental tasks of teens and their families. Research-derived knowledge about risk and protective factors, and proximal causes, correlates and contributors to adolescent drug and related problems inform clinical thinking and interventions with every case. A multisystems approach, MDFT assesses and intervenes in four areas: (1) the adolescent as an individual and a member of a family and peer network; (2) the parent(s), both as individual adults and in his or her role as mother, father or caregiver; (3) the family environment and family relationships, as manifested in day-to-day family transactional patterns; and (4) extrafamilial sources of influence such as peers, school and juvenile justice. Interventions are made within and coordinated across domains. Progress in one area or with one person has implications for and use in others. Individual meetings with parent(s) and teen set the stage for family sessions, and family meetings may offer content and new outcomes that need to be brought to extrafamily meetings with juvenile justice or school personnel. MDFT was developed and tested as a treatment system rather than a one-size-fits-all approach. A treatment system offers different versions of a clinical model that vary according to factors such as clinical sample characteristics (older versus younger adolescents, juvenile justice involved versus no involvement in juvenile justice systems), and treatment parameters (type of clinical setting and treatment dose).

Abstract: Prices are an essential element of the illicit drug market, from both a supply and demand perspective. They are an indicator of drug availability and are an important tool for understanding the workings of drug supply mechanisms. They may also be used to help target law enforcement resources and assist criminal justice agencies with decisions related to prosecution and sentencing (e.g. assets recovery). The EMCDDA has been collecting information on retail drug prices via its Reitox focal points for the last 15 years. Although considerable progress has been made in this area, there is still variation in data collection in Europe. To address this issue, the EMCDDA has released these Guidelines for collecting data on retail drug prices in Europe: issues and challenges in its Manuals series. The Manual raises awareness on specific issues related to collecting data on retail drug prices and offers practical suggestions. It addresses difficulties in obtaining a definition of ’retail’ prices, and discusses the challenge of obtaining a representative sample of illicit, and therefore hidden, transactions. Suggestions are made for a minimum set of variables to be recorded for each observation. Targeted at all those involved in data collection on drug prices in Europe, the Manual reviews the main data-collection methods, current national practices and data-management issues.